We are live on ! Find out more
ACM

Altium Capital Management Portfolio holdings

AUM $42M
This Fund
S&P 500
This Quarter Est. Return
+2.29%
1 Year Est. Return
–
3 Year Est. Return
–
5 Year Est. Return
–
10 Year Est. Return
–
AUM
$363M
AUM Growth
-$18.6M
Cap. Flow
+$5.56M
Cap. Flow %
1.53%
Top 10 Hldgs %
25.94%
Holding
173
New
49
Increased
12
Reduced
23
Closed
40

Top Buys

Rank Stock Value
1
ESPR
Esperion Therapeutics
ESPR
+$20.1M
2
PEPL
PepperLime Health Acquisition Corporation Class A Ordinary Share
PEPL
+$7.18M
3
CBAY
Cymabay Therapeutics
CBAY
+$6.64M
4
NSTG
NanoString Technologies, Inc.
NSTG
+$6.41M
5
QDEL icon
QuidelOrtho
QDEL
+$5.15M

Top Sells

Rank Stock Value
1
ALDX icon
Aldeyra Therapeutics
ALDX
+$7.59M
2
ARQT icon
Arcutis Biotherapeutics
ARQT
+$6.09M
3
CDNA icon
CareDx
CDNA
+$5.7M
4
HAE icon
Haemonetics
HAE
+$5.22M
5
LITS
Lite Strategy Inc
LITS
+$5.04M

Sector Composition

Rank Sector Weight
1 Healthcare 79.63%
2 Financials 7.92%
3 Technology 1.93%
4 Industrials 1.24%
5 Communication Services 0.71%
Name Market Value Portfolio Weight Shares or Principal Change
in Stake 		Capital Flow
INFU icon
51
InfuSystem Holdings
INFU
$236M
$2.98M 0.82%
+175,000
New +$2.78M
ATEC icon
52
Alphatec Holdings
ATEC
$1.42B
$2.92M 0.8%
+255,000
New +$3.01M
HCDIP
53
DELISTED
Harbor Custom Development, Inc. 8.0% Series A Cumulative Convertible Preferred Stock, no par value
HCDIP
$2.9M 0.8%
+185,000
New +$2.87M
CTMX icon
54
CytomX Therapeutics
CTMX
$734M
$2.87M 0.79%
663,800
-569,842
-46% -$3.34M
MORF
55
DELISTED
Morphic Holding, Inc. Common Stock
MORF
$2.84M 0.78%
60,000
– –
EYPT icon
56
EyePoint Inc
EYPT
$1.11B
$2.75M 0.76%
225,000
-145,551
-39% -$1.96M
TMPM
57
DELISTED
Turmeric Acquisition Corp. Class A Ordinary Shares
TMPM
$2.49M 0.69%
254,000
– –
MLTX icon
58
MoonLake Immunotherapeutics
MLTX
$1.53B
$2.47M 0.68%
250,000
– –
STAA icon
59
STAAR Surgical
STAA
$1.15B
$2.37M 0.65%
+26,000
New +$2.79M
LEGN icon
60
Legend Biotech
LEGN
$3.73B
$2.33M 0.64%
+50,000
New +$2.54M
SRSA
61
DELISTED
Sarissa Capital Acquisition Corp. Class A Ordinary Shares
SRSA
$2.2M 0.61%
225,000
– –
TGVCU
62
DELISTED
TG Venture Acquisition Corp. Units
TGVCU
$2.05M 0.57%
+200,000
New +$2.05M
MDGL icon
63
Madrigal Pharmaceuticals
MDGL
$11.8B
$2.03M 0.56%
+24,000
New +$1.97M
CRDF icon
64
Cardiff Oncology
CRDF
$74.7M
$2.02M 0.56%
337,000
-11,888
-3% -$70.9K
GIW
65
DELISTED
GigInternational1, Inc. Common Stock
GIW
$1.99M 0.55%
200,000
– –
DYN icon
66
Dyne Therapeutics
DYN
$4.83B
$1.98M 0.55%
166,636
– –
LAAA
67
DELISTED
Lakeshore Acquisition I Corp. Ordinary Shares
LAAA
$1.97M 0.54%
200,000
– –
MOBX icon
68
Mobix Labs
MOBX
$26M
$1.97M 0.54%
20,000
– –
JYAC
69
DELISTED
Jiya Acquisition Corp. Class A Common Stock
JYAC
$1.95M 0.54%
200,000
– –
ETNB
70
DELISTED
89bio
ETNB
$1.93M 0.53%
+148,000
New +$2.34M
CELC icon
71
Celcuity
CELC
$4.55B
$1.91M 0.53%
145,000
– –
VQS
72
DELISTED
VIQ SOLUTIONS INC
VQS
$1.64M 0.45%
704,687
– –
GBT
73
DELISTED
Global Blood Therapeutics, Inc.
GBT
$1.58M 0.44%
+54,000
New +$1.67M
DHACU
74
DELISTED
Digital Health Acquisition Corp. Unit
DHACU
$1.54M 0.42%
+150,000
New +$1.53M
FATBW
75
DELISTED
FAT Brands Inc. Warrant
FATBW
$1.53M 0.42%
227,000
– –
1 2
3
4 5

Similar funds

TA
TLS Advisors Miami, Florida $42.1M AUM 25.99% 1-Year Est. Return
SIM
Spark Investment Management New York $41.6M AUM 80.97% 1-Year Est. Return
VEPM
Vista Equity Partners Management San Francisco, California $42.7M AUM 16.65% 1-Year Est. Return
VI
Versor Investments New York $40.8M AUM 93.59% 1-Year Est. Return
BCM
Bratton Capital Management Fort Worth, Texas $40.7M AUM 43.1% 1-Year Est. Return
VAM
Vazirani Asset Management New York $43.4M AUM 84.05% 1-Year Est. Return
SCM
Stadium Capital Management New Canaan, Connecticut $40.6M AUM 5.83% 1-Year Est. Return
CAS
CTC Alternative Strategies Chicago, Illinois $44M AUM 43.15% 1-Year Est. Return

Altium Capital Management's Q4 2021 Portfolio in Review

As of Q4 2021, Altium Capital Management held 173 positions worth $363M, down 4.9% from $381M the previous quarter. Its ten largest holdings account for 26% of the portfolio.

Altium Capital Management's Q4 2021 filing shows 49 new, 12 increased, 23 reduced and 40 closed positions. Its largest new stake was Esperion Therapeutics: 2,515,785 shares worth $12.6M. The largest sale was Aldeyra Therapeutics, an estimated $7.59M.

By sector, the portfolio is most concentrated in Healthcare at 80% of assets, down from 82% a quarter earlier, followed by Financials and Technology.

  • Altium Capital Management's largest Q4 2021 buy was Esperion Therapeutics: 2,515,785 shares worth $12.6M.
  • Altium Capital Management added most to Bicycle Therapeutics in Q4 2021, an estimated $4.41M increase.
  • Altium Capital Management's biggest Q4 2021 reduction was Cerus, cutting an estimated $4.27M.
  • Altium Capital Management fully exited Aldeyra Therapeutics in Q4 2021, selling an estimated $7.59M.
  • Altium Capital Management's ten largest holdings make up 26% of its $363M portfolio in Q4 2021.
  • Altium Capital Management opened 49 new positions and closed 40 in Q4 2021.
  • Altium Capital Management's portfolio value fell 4.9% quarter-over-quarter to $363M.

Based on Altium Capital Management's 13F filing for Q4 2021, filed 14 Feb 2022.